key: cord-0974889-yuy6002v
authors: Philbin, Morgan M.; Perez-Brumer, Amaya
title: Promise, perils and cautious optimism: the next frontier in long-acting modalities for the treatment and prevention of HIV
date: 2022-02-07
journal: Curr Opin HIV AIDS
DOI: 10.1097/coh.0000000000000723
sha: 5214dbfe80ad37af197810f4951e7a0a8b3d1d92
doc_id: 974889
cord_uid: yuy6002v

This paper provides a critical review of recent therapeutic advances in long-acting (LA) modalities for human immunodeficiency virus (HIV) treatment and prevention. RECENT FINDINGS: LA injectable antiretroviral therapy (ART) has been approved in the United States, Canada and Europe; the United States also has approved LA injectable preexposure prophylaxis (PrEP) and the World Health Organization has recommended the vaginal PrEP ring. Current LA PrEP modalities in clinical trials include injections, films, rings, and implants; LA ART modalities in trials include subcutaneous injections and long-term oral pills. Although LA modalities hold incredible promise, global availability is inhibited by long-standing multilevel perils including declining multilateral funding, patent protections and lack of political will. Once available, access and uptake are limited by factors such as insurance coverage, clinic access, labor markets, stigma, and structural racism and sexism. These must be addressed to facilitate equitable access for all. SUMMARY: There have been tremendous recent advances in the efficacy of LA ART and PrEP modalities, providing renewed hope that ‘ending the HIV epidemic’ is within reach. However, pervasive socio-structural inequities limit the promise of LA modalities, highlighting the need for cautious optimism in light of the embedded inequities in the trajectory of research, development, and population-level implementation.

The advent of highly active antiretroviral therapy (ART) in 1996 transformed human immunodeficiency virus (HIV) infection into a manageable chronic condition for those in locales where it was available and accessible. Recent biomedical advances in long-acting (LA) modalities for ART and preexposure prophylaxis (PrEP) are once again expanding what is possible as we move toward 'ending the HIV epidemic' [1] . As of February 2022, LA injectable (LAI) ART with two month dosing [2] had been approved by the United States Food and Drug Administration (FDA) and Canadian and European regulators [3] . In 2021, the US FDA approved LAI PrEP and the World Health Organization (WHO) recommended the monthly vaginal ring for PrEP.

Each new LA modality is an important tool in an ever-expanding toolkit and offers novel strategies to reduce barriers to daily pill taking [4, 5] . Although LA modalities have the potential to change the course of the epidemic if provided as an option for all, they are not a panacea. The history of HIV and AIDS has underscored that framing biomedical treatment and prevention as sufficient for 'ending the HIV epidemic' flattens the deeply embedded social, cultural and political processes that drive the epidemic [6, 7] . Historically, this has all too often resulted in incredible HIV technological advances that take a myopic individual-level approach and thus have limited population-level impacts; effective approaches to scaling up LA HIV modalities will require keen attention to socio-cultural dimensions [8] .

LA modalities will not improve adherence without addressing long-standing multilevel perils that continue to constrain uptake of oral ART and PrEP, particularly among marginalized communities. For example, geopolitical determinants including fluctuations in funding for major HIV initiatives, such as the President's Emergency Plan for AIDS Relief (PEP-FAR) and the Global Fund to Fight AIDS, Tuberculosis, and Malaria [9,10 & ,11] , patent protections [12] [13] [14] and lack of political will [15] [16] [17] can limit the incountry availability of approved HIV therapies. Clinical trials are sometimes the only avenue for communities in resource-limited settings to access emerging HIV treatment and prevention modalities, creating ethical questions about engagement in, vs. benefits from, research [18] [19] [20] [21] . Even countries with approved LA modalities have striking inequities in access and uptake due to factors including: provider education, training and attitudes, insurance coverage and access, ability to attend clinic visits (e.g., transportation, labor market restrictions), medical mistrust and broader factors such as racism and sexual oppression [22,23 & ,24,25] . This paper reviews the state of the science regarding LA ART and PrEP to underscore the tremendous recent advances. It also presents how embedded and deep-rooted inequities continue to exist in all phases of the research-to-implementation pipeline, and how these will limit who ultimately stands to benefit from LA modalities. We must attend to these perils, and approach LA HIV modalities with cautious optimism, in order to ensure availability, access and uptake for all.

Long-acting injectable ART, administered every 2 months, has been approved by the US FDA, and Canadian and European regulators for virally suppressed people aged 18 years and over [2] . LAI PrEP, administered every 8 weeks, was approved by the US FDA in December 2021. The WHO recommended the vaginal PrEP ring in 2021 but the International Partnership for Microbicides (IPM) voluntarily withdrew its US FDA New Drug Application in December 2021 [26] . Additional LA ART and PrEP modalities are in all phases of clinical trials (Tables 1 and 2 ). In September 2021, there were 27 nonvaccine LA PrEP products in the pipeline [27] . LA ART modalities under study include injections and oral pills.

LAI ART is a combination of cabotegravir and rilpivirine, branded as Vocabria and Rekambys in Europe and Cabenuva in the United States. In initial clinical trials LAI ART required two injections in the buttocks every 4 weeks and was noninferior to oral ART [28] . In subsequent trials, LAI ART administered every 8 weeks was noninferior to monthly injections [29] ; this has been approved in Europe, Canada, and the United States [30, 31] . LAI ART is only available to virologically suppressed individuals [32] and requires an oral lead-in [33] . Thus, LAI ART cannot substantially expand the number of virally suppressed individuals, though it may facilitate longterm viral suppression among those with episodic oral ART adherence. Also, because nonadherence is higher among minoritized populations (e.g., by race and ethnicity, sexuality, gender, and socioeconomic

The tremendous recent advances in the efficacy of longacting (LA) antiretroviral therapy and preexposure prophylaxis modalities have renewed optimism that 'ending the HIV epidemic' is within reach. However, medical innovations alone are insufficient to overcome pervasive health inequities both globally and within countries.

The promise represented by LA modalities (e.g., injectables, implants, patches, enemas) must be approached with cautious optimism in light of the embedded inequities across all stages of research, development and, most critically, population-level scaleup. Social and behavioral science research can help identify and address these embedded inequities.

To redress global inequities in LA modalities, we must name and address embedded biases in research by examining which individuals are able to enroll, choose to enroll and remain in the clinical trials themselves and who can subsequently benefit from the trial findings. status) [34, 35] , this requirement may exacerbate existing inequities. To address these challenges, the LATITUDE study [36] is currently investigating LAI ART feasibility among nonsuppressed individuals, who must first achieve suppression using an oral lead-in.

Long-acting preexposure prophylaxis modalities LAI PrEP was superior to oral PrEP in HIV Prevention Trials Network (HPTN) studies among cisgender men, transgender women, and cisgender women [37, 38] . These trials are continuing as open-label extension studies and expanding to include acceptability assessments among those under 18 years of age [39, 40] . LA PrEP is also in various stages of clinical trials including: monthly oral pills; vaginal and rectal gels; vaginal rings, films, and inserts; intramuscular and subcutaneous injections; implants; enemas; and micro-array patches [27] .

As of June 2021, LA PrEP products in Phase III/IV clinical trials include a once-monthly vaginal ring, a once-monthly oral pill and a twice-yearly subcutaneous injection. Further, with goals of increased inclusivity, these studies include recruitment targets to increase participation among African-American and gender non-binary individuals [41, 42] . The WHO has recommended the vaginal ring for PrEP [43] even though it reduced HIV infection risk by only 27-35% in Phase III studies, likely due to challenges with long-term adherence (this compares with 95% efficacy for LAI PrEP) [39, 43] .

One of the perils of LA modalities is that people who participated in the research that demonstrated their efficacy may not have equitable access to LA modalities once the modalities are approved and distributed. To some extent, this results from embedded biases in research that include where the trials are conducted, who is recruited for clinical trial enrollment, who is able to À and chooses to À enroll, and who benefits from post-research findings.

Though clinical trial eligibility criteria are necessary to determine a drug's efficacy, a lack of transparency regarding these criteria can directly affect participant trust [20, 44, 45] and willingness to engage with LA modalities once approved. For example, cisgender women were excluded from the initial DIS-COVER trial (2016-2019) [46] that tested Descovy for PrEP among cisgender men and transgender women. Due to activism around their exclusion, a trial with cisgender women [47] began in 2021. Also, while the HPTN LAI PrEP trial [37] had an enrollment quota of 10% transgender women, it excluded individuals with buttock implants or fillers, a common practice among transgender women [48] . These exclusions are particularly salient since transgender women face increased HIV vulnerability [49] . Not all people choose to participate in clinical trials, and it is important to understand what motivates these choices for different people. Given the large number of LA modalities in development, sustained attention must also be given to informed refusal [50] , namely individuals' decisions to not consent for research participation, or the ways they may assert their own agency during trial participation. The two major oral PrEP trials among cisgender women, FEMPrEP [51] , and VOICE [52] , demonstrated the unique ways that cisgender women may choose to 'opt out' or engage in 'informed refusal' regarding PrEP use [53] . Studying informed refusal will make visible key silences and identify these individuals not as data omissions but rather as points of resistance and opportunities that offer insight into potential barriers to future access, uptake and sustained use [50,54,55,56 && ]. Such insights are particularly important as new modalities are becoming more invasive (e.g., injection vs. pill) and may have different gender-based pharmacokinetics [57] .

The vast majority of LA ART and PrEP clinical trials occur in South America, Asia, and sub-Saharan Africa due to high HIV incidence in these regions. While Global South participants often constitute the majority of clinical trial participants, the availability of the drug under study in these regions is often limited to clinical trial participation due to scant posttrial access. Yet, trial results are often used as the basis for the approval of HIV treatment and prevention modalities in the United States, Canada, and Europe (i.e., paralleling current LAI ART approval) vs. distribution in the Global South [20, 58] . Also, despite differences in risk reductions (95% vs. approximately 30%), LAI PrEP was approved in the United States while the (less effective) ring is under review in sub-Saharan Africa, and has been approved in Zimbabwe [39, 43, 59] . Availability is also tempered by continued decreases in multilateral funding (e.g., PEPFAR) and patent protections that make medications prohibitively expensive. Though collaborations are forming to accelerate availability (e.g., by the International AIDS Vaccine Initiative, Scripps Research, and the US National Institutes of Health), affordable LA modalities will also require generic drug pricing and patent waivers [60, 61] .

The need to ensure equitable access and uptake Even once ART and PrEP are available, deep-seated inequities can still affect their access and uptake. For example, in the United States, AIDS-related mortality overall decreased once oral ART was developed, but declines were greater among white and economically-advantaged populations [62] . Similarly, with oral PrEP, 40% of white individuals in the United States with PrEP indications received a prescription in 2018, vs. 6% of African Americans and 11% of Latinx individuals [63, 64] . Oral PrEP use was 3-times lower for women than men relative to new HIV diagnoses [63] and average length of use was 5.8 months for women vs. 8.4 months for men [65, 66] .

Potential pathways through which socioeconomic status, race and ethnicity, sexuality, and gender may affect ART and PrEP access and uptake in the United States include whether providers offer them [67 & ]; healthcare and insurance access (e.g., Medicaid expansion) [68]; medical mistrust [69] ; perceived risk [70] ; clinical support and wraparound services [71] ; caregiving demands [71, 72] ; food insecurity [73] ; drug use [74] ; stigmatization [75, 76] ; and transportation and employment [24, 25, 77, 78] . Patients' social contexts are unlikely to change alongside the advent of new biomedical modalities; many barriers to access and uptake of oral formulations will still exist for long-acting modalities [72,77,78,79 && ,80] . These systemic barriers may also be perpetuated by LAI ART eligibility criteria À namely viral suppression À as this differs by age [81], race and ethnicity [82 & ], public insurance [83] , and gender [84] .

Variations in access and uptake may also differ by LA modality type. LAI ART and PrEP may increase adherence because they are clinic vs. patient administered. However, LAI modalities tether patients to clinics with little room for variation, increasing the cost of administration. In contrast, LA oral and subcutaneous formulations are self-administered and may increase patient autonomy, but also potentially lower adherence. Patients' social contexts must be acknowledged to address known challenges to adherence, such as oral lead-in concerns, and issues related to long pharmacokinetic tails and the potential need to return to oral medications [4, 85] . Patients have expressed concerns about switching from oral to LA ART as it requires a new drug regimen, may have different adverse effects, and it limits their control over daily dosing [77, 86, 87] . Patients have also noted potential stigma and workplace-based challenges associated with the frequency of LA ART-related clinic visits [72,79 && ,88]. Access to LA ART will not be equally distributed in settings like the United States that lack universal healthcare. Cabenuva costs approximately $50 000 annually and there is no generic equivalent. Although the US-based AIDS Drug Assistance Program (ADAP) provided HIV medication to 284 973 low-income individuals in 2018 [89] , ADAP access is state administered and not universal. As of October 2021, only 22 US states had updated their ADAP formulary after Cabenuva's approval: of these, 10 covered Cabenuva, and 12 did not. Thus, patients outside those 10 states that cover Cabenuva may be unable to access LAI ART, especially since the manufacturer's patient assistance program does not currently cover ADAP patients, nor those outside of the United States. Similar financial inequities will likely exist with LA PrEP. Although its cost remains unknown, it will likely be more expensive than oral PrEP, making it cost-prohibitive for many [90] . Unless structural supports (e.g., insurance, universal healthcare) are introduced, LA HIV modalities will exacerbate the cost-related inequities evidenced in oral ART and PrEP access.

Issues of availability, access, and uptake must also be contextualized within intersecting inequities À such as homelessness, incarceration, mental health and substance use [91] [92] [93] . LA modalities are also available to treat mental health and substance use conditions [94, 95] , and patients' experiences with those modalities (e.g., Vivitrol for opioid use disorder) may affect their willingness to engage in LA ART and PrEP [79 && ]. The additional clinical steps for delivering LA HIV modalities to vulnerable communities may also complicate the provision of a 'one stop shop' approach to service integration, including for unhoused or recently incarcerated individuals.

As LA HIV treatment and prevention modalities continue to advance, research and practice must acknowledge and address the historical and social contexts that limit global availability and access. The integration of social and behavioral scientists into clinical trial design and subsequent implementation studies may be of particular use to identify multilevel approaches to increase inclusion and equity at all stages of the research-to-implementation pipeline [96] . In contexts where LA HIV modalities are available, further research should address access and uptake within healthcare settings, for example how providers may serve as gatekeepers who determine which patients are 'ready' to switch from oral to LA formulations (e.g., by developing patient-provider decision aids to choose between LAI vs. oral ART or whether to begin PrEP, and in which modality) [97] . Various healthcare delivery models (e.g., telehealth and mobile vans) should be explored to facilitate equitable and person-centered utilization of prevention and treatment methods, as these models have been successful for delivering naloxone, clean syringes and COVID-19 vaccines.

Research also needs to address the multilevel drivers of health policy initiatives and patent protections, including incorporating intersectionality-enhanced frameworks, [98] to facilitate an equitable scale-up of LA treatment and prevention modalities for all.

There have been tremendous advances in LA ART and PrEP modalities, with even more products in the pipeline. Yet the perils that constrain their availability, access and uptake demonstrate the need for cautious optimism as to whether 'ending the HIV epidemic' is within reach. Biomedical technologies, no matter how innovative, cannot reach their full promise without applying social and behavioral strategies to address context-specific factors. Such approaches will improve how these LA modalities are developed and tested, distributed, and who can access them (or opt-out if they so choose). This is particularly salient for scale-up in low-resource settings where context-specific challenges have historically impeded wide-scale rollout of HIV prevention and treatment technologies [99] . As the history of the HIV and AIDS response has demonstrated, focusing solely on the medication, clinic, and patientÀ provider interactions is insufficient: tackling the social and political dimensions that limit equitable access requires political struggle, social movements, and global accountability. Social and behavioral sciences should be leveraged as complementary tools to biomedical advances to better understand the lived experiences of marginalized community members; the failure to do so will increase medical paternalism and hinder patientÀprovider relationships. In order for LA HIV modalities to truly fulfill their promise of 'ending the HIV epidemic', equity in availability, access and uptake must be addressed on a global scale.

We would like to acknowledge and thank Dr Richard Parker and Dr Jesse Clark for their thorough and thoughtful comments during the development of this paper. We also want to acknowledge Rachel Maggi for her invaluable support in compiling the tables and supporting the development of the section on the state of the science. 

There are no conflicts of interest.

Papers of particular interest, published within the annual period of review, have been highlighted as: This qualitative study conducted interviews with women living with HIV to assess interest for LAI ART. A particularly meaningful finding from this study came from women with a past history of substance use who had concerns about LAI ART triggering a recurrence. While other substance users did not have concerns, this insight has implications for LAI ART uptake among individuals in this at-risk group.

80. Philbin MM, Bergen S, Parish C, et al. 

Fast-Track À Ending the AIDS epidemic by 2030

CABOTEGRA-VIR, RILPIVIRINE) for Use Every Two Months, Expanding the LabelL of the First and only complete long-acting HIV Treatment

Injectable HIV therapy would have to cost less than $131 a year to be costeffective in Africa

The promise of improved adherence with long-acting antiretroviral therapy: what are the data?

The promise and pitfalls of long acting injectable agents for HIV prevention

Bridging the social and the biomedical: engaging the social and political sciences in HIV research

Beyond the distinction between biomedical and social dimensions of HIV prevention through the lens of a social public health

Moving beyond biomedicalization in the HIV response: implications for community involvement and community leadership among men who have sex with men and transgender people

Examining adherence barriers among women with HIV to tailor outreach for long-acting injectable antiretroviral therapy

The LAIs are coming! Implementation science considerations for long-acting injectable antiretroviral therapy in the United States: a scoping review

This scoping review article used the PRISM model to review the ever-expanding literature on LAI ART implementation. The review revealed the need for more data and research on the acceptability of LAI ART among certain subgroups, cost effectiveness, patient satisfaction and outcomes

& the Global Fund to Fight AIDS, Tuberculosis and Malaria

Duty of treatment human rights and the HIV/AIDS pandemic. Yale Hum Rights Dev Law

Pharmaceutical companies and global lack of access to medicines: strengthening accountability under the right to health

Medical pharmaceuticals and distributive justice

Good politics, bad politics: the experience of AIDS

AIDS is not over

A Critical analysis of the Brazilian response to HIV/AIDS: lessons learned for controlling and mitigating the epidemic in developing countries

Biko and AIDS: reflections on the principle of beneficence in South African medical ethics

Adherence and the lie in a HIV prevention clinical trial

Ethics and preexposure prophylaxis for HIV infection

Why don't you go into suburbs? Why are you targeting us?: trust and mistrust in HIV vaccine trials in South Africa

Global capitalism as a societal determinant of health: a conceptual framework

Long-acting antiretrovirals: a new era for the management and prevention of HIV infection

This review problematizes the 'one-size-fits-all' approach to the administration of LAI ART and suggests that future research must consider the significant interindividual variability in LAI ART pharmacokinetics. This review also offers therapeutic drug monitoring as a potential solution to improve the management of LAI ART in individual patients

Gendered social institutions and preventive healthcare seeking for black men who have sex with men: the promise of biomedical HIV prevention

IPM Statement on US Food and Drug Administration Review of Dapivirine Vaginal Ring

The Future of ARV-Based Prevention and More. AVAC

Long-acting cabotegravir þ rilpivirine for HIV-1 treatment: ATLAS week 96 results

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2 M), 48-week results: a randomised, multicentre, open-label, phase 3b, noninferiority study

CABOTEGRA-VIR, RILPIVIRINE) for Use Every Two Months, Expanding the LabelL of the First and only complete long-acting HIV Treatment

Long-acting injectable HIV treatment approved in the EU: includes twomonthly dosing j HTB j HIV i-Base

Available at: https:// cabenuvahcp.com/clinical-trials

Approves Cabenuva and Vocabria for the Treatment of HIV-1 Infection

A5359: The LATITUDE Study -ACTG Network. Available at: https:// actgnetwork.org/studies/a5359-the-latitude-study

The HIV Prevention Trials Network j Prevention Now

The HIV Prevention Trials Network j Prevention Now

United States (US) National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), US National Institutes of Health (NIH)

The HIV Prevention Trials Network j Prevention Now

A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate the Efficacy and Safety of Oral Islatravir Once-Monthly as Preexposure Prophylaxis in Cisgender Women at High Risk for HIV-1 Infection. Clinical Trial Registration NCT04644029, clinicaltrials.gov

A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS-6207 in Combination With an Optimized Background Regimen in Heavily Treatment Experienced People Living With HIV-1 Infection with Multidrug Resistance. Clinical Trial Registration NCT04150068, clinicaltrials.gov

International Partnership for Microbicides. A Long-Acting Ring for Women's HIV Prevention

The wisdom of mistrust: qualitative insights from transgender women who participated in PrEP research in Lima

Medical mistrust, discrimination, and the domestic HIV epidemic

Available at

Gilead Announces New Arm of HIV Womens Prevention Study. Available at

Transgender women's concerns and preferences on potential future long-acting biomedical HIV prevention strategies: the case of injections and implanted medication delivery devices (IMDDs)

Informed refusal: toward a justice-based bioethics

Preexposure prophylaxis for HIV infection among African women

Tenofovir-based preexposure prophylaxis for HIV infection among African women

Women's experiences with oral and vaginal preexposure prophylaxis: the VOICE-C qualitative study in

Native American DNA: Tribal Belonging and the False Promise o Genetic Science

Reassessing the ethics of molecular HIV surveillance in the era of cluster detection and response: toward HIV data justice

Reckoning with histories of medical racism and violence in the USA

Although not explicitly mentioned, it can be inferred that the resulting medical mistrust that marginalized groups in the

Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial

Global implementation of PrEP for HIV prevention: setting expectations for impact

Dapivirine Vaginal Ring for HIV Prevention No Longer Under Consideration by the FDA

Impact of long-acting therapies on the global HIV epidemic

The Joint United Nations Programme on HIV/AIDS 95-95-95 targets: worldwide clinical and cost benefits of generic manufacture

Examination of inequalities in HIV/AIDS mortality in the United States from a fundamental cause perspective

The prevalence of preexposure prophylaxis use and the preexposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States

Vital signs: status of human immunodeficiency virus testing, viral suppression, and HIV preexposure prophylaxis -United States

Staying on PrEP is Significantly Different for PrEP Users With Commercial Insurance Versus Medicaid. TheBodyPRO.com. 2019. Available at

Persistence with HIV preexposure prophylaxis in the United States

Improving HIV preexposure prophylaxis implementation for women: summary of key findings from a discussion series with women's HIV prevention experts

lack of HIVrelated health literacy and risk perception, difficulty assessing risk, provider bias, cost, contextual factors, and inadequate infrastructure and resources. This article helps inform potential barriers for future uptake of LA PrEP modalities as they move through the research and development pipeline. 68. The Kaiser Family Foundation. Status of State Action on the Medicaid Expansion Decision. The Henry J. Kaiser Family Foundation

Race-based medical mistrust, medication beliefs and HIV treatment adherence: test of a mediation model in people living with HIV/AIDS

Knowledge, attitudes, and likelihood of pre-exposure prophylaxis (PrEP) use among US women at risk of acquiring HIV

Longitudinal study of mental health and psychosocial predictors of medical treatment adherence in mothers living with HIV disease

Experiences with long acting injectable ART: a qualitative study among PLHIV participating in a Phase II study of cabotegravir þ rilpivirine (LATTE-2) in the United States and Spain

Food insecurity is associated with poor HIV outcomes among women in the United States

Substance use, violence, and antiretroviral adherence: a latent class analysis of women living with HIV in Canada

A mixed methods study of anticipated and experienced stigma in healthcare settings among women living with HIV in the United States

Stress, social support, and HIVstatus disclosure to family and friends among HIV-positive men and women

A multisite study of women living with HIV's perceived barriers to, and interest in, long-acting injectable antiretroviral therapy

Interest in long-acting injectable preexposure prophylaxis (LAI PrEP) among women in the women's interagency HIV study (WIHS): a qualitative study across six cities in the United States

Racial and ethnic disparities in sustained viral suppression and transmission risk potential among persons aged 13-29 years living with diagnosed HIV infection, United States

This article assessed rates of sustained viral suppression among racial/ethnic groups aged 18-39 in the U.S. The researchers found that sustained viral suppression in this age group was suboptimal and transmission risk was high. In addition, it was found that racial/ethnic groups were disproportionately affected, with Black individuals having the lowest prevalence of sustained viral suppression. These results have implications for LAI ART uptake

Disparities in viral suppression and medication adherence among women in the USA

Understanding cross-sectional racial, ethnic, and gender disparities in antiretroviral use and viral suppression among HIV patients in the United States

An Open Label, Phase 1 Study to Evaluate the PK, Safety, Tolerability and Acceptability of Long Acting Injections of the HIV Integrase Inhibitor, Cabotegravir (CAB; GSK1265744) in HIV Uninfected Chinese Men

The dose response: perceptions of people living with HIV in the United States on alternatives to oral daily antiretroviral therapy

A dream come true: perspectives on long-acting injectable antiretroviral therapy among female sex workers living with HIV from the Dominican Republic and Tanzania

Efficacy and freedom: patient experiences with the transition from daily oral to long-acting injectable antiretroviral therapy to treat HIV in the context of Phase 3 trials

Cost-effectiveness of long-acting PrEP among MSM/TGW in the US

Psychosocial Mediators of Antiretroviral Nonadherence in HIV-Positive Adults with Substance Use and Mental Health Problems

Mental health, substance use and viral suppression in adolescents receiving ART at a paediatric HIV clinic in South Africa

Factors affecting linkage to care and engagement in care for newly diagnosed HIV-positive adolescents within fifteen adolescent medicine clinics in the United States

Creating demand for long-acting formulations for the treatment and prevention of HIV, tuberculosis, and viral hepatitis

Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population

Advancing long-acting and extended delivery HIV prevention and treatment regimens through behavioural science: NIH workshop directions

Online decision aid addresses health disparities among MSM j Health Communication Core

Intersectionality-Enhanced Consolidated Framework for Implementation Research

Long-acting injectable preexposure prophylaxis for HIV prevention in South Africa: is there a will and a way?

Noninferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current INI-NNRTI-, or PI-based Antiretroviral Regimen in HIV-1-infected Adults Who Are Virologically Suppressed. Clinical Trial Registration NCT02951052, clinicaltrials.gov

The ATLAS clinical trial found that the combination of cabotegravir and rilpivirine administered as an intramuscular injection every 4 weeks was noninferior to oral ART. This trial, in addition to the FLAIR clinical trial (which was conducted among treatment naïve individuals) lead to the approval of the use of LAI ART for people 18 years of age and older by regulatory bodies in the U.S., Canada, and Europe. ATLAS-2M is a subsequent clinical trial that found that LAI ART

Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression

Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every 8 Weeks or Every 4 Weeks in HIV-1-infected Adults Who Are Virologically Suppressed. Clinical Trial Registration NCT03299049, clinicaltrials.gov

Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor Single Tablet Regimen in HIV-1 Infected Antiretroviral Therapy Naive Adult Participants. Clinical Trial Registration NCT02938520, clinicaltrials.gov

Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection

Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study

&& National Institute of Allergy and Infectious Diseases (NIAID). A Phase

Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women Who Have Sex With Men

The HPTN 083 clinical trial found that cabotegravir administered as an intramuscular injection every 8 weeks was superior to oral PrEP regimens among cisgender men and transgender women. A similar clinical trial, HPTN 084, conducted among cisgender women also found that LAI PrEP was superior to oral PrEP, with even greater effectiveness than the 083 trial. Currently two additional clinical trials

Cabotegravir for HIV prevention in cisgender men and transgender women

A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women. Clinical Trial Registration NCT03164564, clinicaltrials.-gov

HPTN 084 Study Demonstrates Superiority of Injectable Cabotegravir to Oral FTC/TDF for the Prevention of HIV in Cisgender Women in Sub-Saharan Africa j The HIV Prevention Trials Network

Double-Blind, Placebo-Controlled Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women. Clinical Trial Registration NCT01539226

Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women

Placebo-Controlled Phase 3 Safety and Effectiveness Trial of a Vaginal Matrix Ring Containing Dapivirine for the Prevention of HIV-1 Infection in Women

Use of a vaginal ring containing dapivirine for HIV-1 prevention in women

Open-Label Trial To Assess Continued Safety Of And Adherence To The Dapivirine (25 Mg) Vaginal Ring-004 In Healthy, HIV-Negative Women. Clinical Trial Registration NCT02862171, clinicaltrials.gov

Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study

A Phase 3B Open-Label Follow-on Trial to Assess the Continued Safety of and Adherence to a Vaginal Ring Containing Dapivirine in Women

The Ring Study was the first clinical trial to assess the effectiveness of monthly dapivirine vaginal rings as long-acting PrEP among cisgender women in Sub-Saharan Africa. This trial and subsequent trials have found that the rings were safe and effective and have been recommended by the WHO in their HIV guidelines

Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study

A Phase III Study to Evaluate Long-Acting Antiretroviral Therapy in Non-Adherent HIV-Infected Individuals

Although this study also requires an oral lead prior to LAI ART initiation, the inclusion of nonadherent individuals in this trial has the potential to eventually expand the current patient eligibility for LAI ART

Gilead's Investigational Lenacapavir Demonstrates Sustained Long-Acting Efficacy Through Week 26 in Data Presented at CROI

A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of Oral Islatravir Once-Monthly as Preexposure Prophylaxis in Cisgender Men and Transgender Women Who Have Sex with Men, and are at High Risk for HIV-1 Infection

Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males À A Sub-study of HPTN 083

Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Females À A Sub-study of HPTN 084

A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral MK-8591 Once-Monthly in Participants at Low-Risk for HIV-1 Infection

A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Radiopaque Matrix MK-8591 Implant in Participants at Low-Risk for HIV-1 Infection. Clinical Trial Registration NCT05115838, clinicaltrials.gov

Phase 1 Safety and Pharmacokinetics Study of MK-2048/Vicriviroc (MK-4176)/MK-2048A Intravaginal Rings

Phase 1 safety and pharmacokinetics study of MK-2048/Vicriviroc (MK-4176)/MK-2048A intravaginal rings

Phase 1 Pharmacokinetic Trial of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048

Phase 1 pharmacokinetic trial of 2 intravaginal rings containing different dose strengths of vicriviroc (MK-4176) and MK-2048

A Phase 1, Randomized Pharmacokinetics and Safety Study of Extended Duration Dapivirine Vaginal Rings

Phase 1 pharmacokinetics and safety study of extended duration dapivirine vaginal rings in the United States

Phase 1, Open-Label Study in Healthy HIV-Negative Women to Evaluate the Pharmacokinetics, Safety and Bleeding Patterns Associated With 90-Day Use of Matrix Vaginal Rings Containing 200 mg Dapivirine and 320 mg Levonorgestrel. Clinical Trial Registration NCT03467347, clinicaltrials.gov

CAPRISA 018: A randomised controlled trial to assess the safety, acceptability and pharmacokinetics of a sustained-release tenofovir alafenamide sub-dermal implant for HIV prevention in women -ERA-LEARN

A Randomized, Double Blind, Placebo-Controlled, Phase 1 Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults

Acceptability of a dapivirine/placebo gel administered rectally to HIV-1 seronegative adults (MTN-026)

Phase 1 Study of the Safety, Toxicity, Pharmacokinetics, Pharmacodynamics and Luminal Distribution of Single-dose DuoGel Through Rectal Administration

Examining the safety, pharmacokinetics, and pharmacodynamics of a rectally administered IQP-0528 gel for HIV preexposure prophylaxis: a first-in-human study

An Open Label Randomized Phase 1 Pharmacokinetic Study of Dapivirine Gel Administered Rectally to HIV-1 Seronegative Adults

Comparing applicator vs. 'as lubricant' delivery of rectal dapivirine gel (MTN-033)

A Monocentric Phase I Safety, Acceptability, and Pharmacokinetic Trial of OB-002H Gel Administered Vaginally and Rectally in Open-Label and Randomised, Double-Blind, Placebo-Controlled Cohorts of HIV-1 Seronegative Adults. Clinical Trial Registration NCT04791007, clinicaltrials.gov

Evaluation of the safety, acceptability, and pharmacokinetic profile of a gel formulation of OB-002 in healthy volunteers

DREAM-01: Optimization of a Tenofovir Enema for HIV Prevention

Tenofovir Rectal Douche Provides Protective Drug Levels in MSM Colon Tissue À on-demand, behaviorally-congruent. Available at

Double-Blind Phase 1 Safety and Pharmacokinetic Study of Q-Griffithsin Enema Administered Rectally to HIV-1 Seronegative Adults

A Phase I, Open-label Multiple Dose Safety, Pharmacokinetic, Pharmacodynamic, and Acceptability Study of Tenofovir Rectal Douche

PK/PD, Acceptability, and Desirability of a Novel HIV Prevention Douche Among Adolescent Men (DREAM)

A Phase 1 Open Label Study Evaluating the Distribution of a Tenofovir Douche in Combination With Tap Water Douching and Simulated Receptive Anal Intercourse (DREAM-02)

Placebo-controlled, Dose Escalation Trial to Evaluate the Safety and to Assess Local and Systemic Pharmacokinetics of DS003 Vaginal Tablets Administered to Healthy HIV-negative Women. Clinical Trial Registration NCT02877979, clinicaltrials.gov

08 À Pharmacodynamic Activity of DS003, a Novel gp120 Blocker, When Administered to Women as a Vaginal Tablet. Presented at: HIV Research For Prevention (HIVR4P)

02 À Pharmacodynamic Activity of DS003, a Novel gp120 Blocker, When Administered to Women as a Vaginal Tablet. Presented at: HIV Research For Prevention (HIVR4P)

A Phase 1 Open Label Safety and Pharmacokinetic Study of Rectal Administration of a Tenofovir Alafenamide/Elvitegravir Insert at Two Dose Levels. Clinical Trial Registration NCT04047420, clinicaltrials.gov

Double Blinded Study of the Safety and Pharmacokinetics of Two Vaginal Film Formulations Containing the Integrase Inhibitor MK-2048